Insmed Inc (INSM)

[read_this_n0w]

Point is they have 124 million cash, no debt and currently cash flow neutral since Q3 2009 with roughly with 11 mln annual revenue from italy and about 15mln worth of iplex stockpile .
Total sharecount roughly 130 million.

So market cap 143 minus 124 cash =

That leaves a stockmarket value of 20 million dollar for both their entire IP portfolio as well as their iplex stockpile which has a proven value in italy

Italy alone creates revenue of 10mln on 60-100 patients.

ie whatever timeframe, or trader you are, that is very very much undervalued by all standards.. let alone if ALS is a real card to play again for the company as recent data suggest.
Italian data allready hinted at positives in usage of Iplex, the SMALL (but monitored in accordance and with fda discussed guidelines) USA patient results same to indicate the same.


ALS market is 30.000 patients in the USA that are all going to die within 5-7 years, since about 5yrs is the life expectancy of someone with ALS. And Insmed sell IPLEX in italy for about 140.00 per patient per year. (Insmed spent about 500-600mln developping both iplex, running trials and figuring out how to produce this very difficult biologic (which iplex is)), so cost recovery is why price is so high, not the production cost.)


Retinopathy allready is a likely and high odds use for iplex :
http://www.rop.gu.se/prevention